



Zodiac Capital Limited, ACN 126 263 170
Level 1, 275 George Street, Sydney NSW 2000
Australia
Phone +61 2 9299 9270
Fax +61 2 9299 9276

FOR IMMEDIATE RELEASE

IMMUNOXYEL DEMONSTRATES POSITIVE EFFECT IN TB AND HIV CO-INFECTION CASES – CLINICAL TRIALS CONTINUE TO HIGHLIGHT THE POTENTIAL OF IMMUNOXYEL IN THE TREATMENT OF TB AND TB/HIV

Sydney NSW, December 22, 2008 -- Zodiac Capital Limited (NSX: ZOD) advises that results of a recent clinical trial in 60 patients with TB and HIV co-infection by its product licensor and partner Ekomed LLC have just been published in the December issue (Volume 44; Pages 392-396) of Cytokine – the official journal of the International Cytokine Society.

In the latest series of studies two of the Company's supplements, Immunoxel (Dzherelo) and Anemin - when combined with conventional anti-tuberculosis therapy (ATT) - were shown to modulate the output in cytokines and to provide a radical difference and improvement in the supplement treated patients than in patients on chemotherapy alone.

In the study sixty HIV-positive patients with active pulmonary TB were equally divided into three matched groups to receive either ATT, ATT+Dzherelo, or ATT+Dzherelo+Anemin. Peripheral blood samples were measured by ELISA for plasma levels of IL-2, IL-6, TNF-alpha, IFN-gamma and IFN-alpha. After 6 months of follow-up Dzherelo and Dzherelo+Anemin combinations produced 61% (P=0.005) and 44.4% (P=0.06) higher levels of IL-2, whereas in ATT group they were reduced by 33.1% (P=0.002). The levels of IL-6 increased by 17% (P=0.15) in ATT group, but declined in both immune intervention groups by 26.2% (P=0.007) and 21.3% (P=0.22). TNF-alpha was suppressed in the two immunotherapy groups by 19.1% (P=0.06) and 76.3% (P=0.02), respectively, but had risen by 14% (P=0.42) in ATT patients. The pattern of production of IFN-gamma was opposite to that of TNF-alpha, but statistical significance was stronger in patients receiving ATT and Dzherelo+Anemin than in Dzherelo group: -34% (P=0.004), +31.9% (P=0.008), and +17.3% (P=0.33), respectively. Moderately decreased levels of IFN-alpha were observed in all treatment arms (range 0.9-16.6%) but differences were not significant. Despite considerable intra-group variation in cytokine production, the baseline inter-group averages were not statistically different indicating that the results were not biased by sample heterogeneity.

"Our present findings are consistent with the unique properties of Immunoxel demonstrated in past studies in TB patients and in the earlier recent clinical study in 40 TB/AIDS patients, which was published this year in the International Journal of Immunopharmacology," said Mr. Volodymyr Pylypchuk, scientific director of the Ekomed LLC. "We now have evidence that HIV viral load reduction and increase in CD4 counts correlate with very intriguing and favourable changes in cytokine production. These changes are very consistent and will allow us to establish the correlates of immune response associated with favourable clinical outcome, especially in patients with dual HIV and TB infection".



Zodiac Capital Limited, ACN 126 263 170
Level 1, 275 George Street, Sydney NSW 2000
Australia
Phone +61 2 9299 9270
Fax +61 2 9299 9276

In earlier published clinical trials, the oral immunomodulator, Immunoxel (Dzherelo) has been shown to be safe and effective as an adjunct immunotherapy in TB patients including patients with multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB). Similar benefits were observed previously in patients with TB who were also infected with HIV.

The World Health Organisation (WHO) estimates that globally, about one-third of the world's population is infected with the Mycobacterium tuberculosis bacteria that cause TB, and each year approximately 9 million people become ill with the disease, and 2 million of those die. TB patients with HIV are 30 times more likely to die and treatment options for them are limited. TB is currently regarded as pandemic and a major threat to world health.

About Ekomed LLC: Ekomed LLC, based in Kiev, is a research-driven phyto-pharmaceutical company dedicated to promote science and patient well-being.

Ekomed discovers, develops, manufactures and markets botanical medicines that in many cases address unmet medical needs. The Company undertakes ethically-responsible basic and clinical research efforts to support and increase its product adjunct treatment options

About Zodiac Capital Limited: Zodiac Capital is a boutique investment banking group publicly listed on the NSX in Australia.

Zodiac's project investment activities are focused on the creation, syndication and management of investment projects for itself – as a principal, its shareholders and for its syndication and/or investor partners. Syndication and investor partners include wholesale investors and high net worth individuals as well as retail investors introduced to publicly listed interests through Zodiac appointed licensed retail distribution partners.

CONTACT: For further detail or inquiry please contact

Dr Allen Bain allen.bain@zodiaccap.com

Peter Squire peter.squire@zodiaccap.com

Zodiac Capital Limited

Level 1, 275 George Street

Sydney NSW 2000

Tel: +61(0)2 9299 9270